The results of a phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma (RRMM) patients will be orally presented at ASCO 2018. This study is sponsored by Incyte.

Continue Reading

A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma (RRMM) patients (Incyte sponsored study).

Continue Reading

A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone among high risk relapsed/ refractory multiple myeloma patients (BMS sponsored study).

Continue Reading

Recombinant human arginase 1 (rhArg1) in patients with advanced, arginine auxotrophic solid tumors: dose escalation, safety and PK/PD (Bio-Cancer Treatment International Ltd. sponsored study).

Continue Reading

A phase 2 single arm study of safety of elotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone for newly diagnosed or relapsed/refractory multiple myeloma patients (BMS sponsored study).

Continue Reading

A phase 2 study of pomalidomide as a replacement for lenalidomide for multiple myeloma patients relapsed or refractory to a lenalidomide-containing combination regimen (Celgene sponsored study).

Continue Reading

A phase 2 study of weekly 70 mg/m2 carfilzomib for multiple myeloma patients refractory to 27 mg/m2 carfilzomib (Amgen sponsored study)

Continue Reading